Residual Fatigue in Unipolar and Bipolar Depression: A Systematic Review

Overview

Journal Neuropsychopharmacol Rep

Date 2025 Jan 9

PMID 39783764

Authors

Michal Pastuszak

Wieslaw Jerzy Cubala

Katarzyna Jakuszkowiak-Wojten

Aleksander Kwasny

Damian Swieczkowski

Maria Galuszko-Wegielnik

Affiliations

Soon will be listed here.

Abstract

Background: Residual fatigue is a common and debilitating symptom in patients with unipolar and bipolar depression, even after achieving partial or full remission. It significantly impacts patients' quality of life and increases the risk of relapse. This systematic review aims to evaluate the prevalence and effectiveness of therapeutic options for residual fatigue in individuals with unipolar major depressive disorder (MDD) and bipolar disorder (BD).

Methods: A comprehensive search was conducted in the PubMed, SCOPUS, and Web of Science databases up to September 2024. The protocol for this systematic review was registered in PROSPERO. The search strategy included terms related to depression and residual fatigue. Studies were included if they provided data on adult patients diagnosed with MDD or BD, and if they measured the prevalence or treatment of residual fatigue. Risk of bias was assessed using the Cochrane Risk of Bias tool for randomized controlled trials (RCTs) and the Newcastle-Ottawa Scale for non-randomized studies.

Results: Twenty studies were included in the review. The vast majority reported on MDD, and single papers investigated BD. Residual fatigue was reported by up to 83% of patients, and moderate to severe residual fatigue affected a smaller percentage. Pharmacological treatments, such as modafinil and to a lesser extent atomoxetine, demonstrated short-term reductions in residual fatigue.

Conclusion: Residual fatigue remains a significant challenge in the treatment of depression, persisting in a large portion of patients despite remission. Pharmacological interventions like modafinil appear promising, but more research is needed, especially in BD. Standardized assessment tools and longer-term studies are essential to better understand and treat residual fatigue.

Trial Registration: PROSPERO identifier: CRD42024543087.

References

Daumas L, Corbel C, Zory R, Corveleyn X, Fabre R, Robert P . Associations, overlaps and dissociations between apathy and fatigue. Sci Rep. 2022; 12(1):7387. PMC: 9072543. DOI: 10.1038/s41598-022-11071-5. View

Sharpe M, Wilks D . Fatigue. BMJ. 2002; 325(7362):480-3. PMC: 1124000. DOI: 10.1136/bmj.325.7362.480. View

Goss A, Kaser M, Costafreda S, Sahakian B, Fu C . Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013; 74(11):1101-7. DOI: 10.4088/JCP.13r08560. View

Bahji A, Mesbah-Oskui L . Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis. J Affect Disord. 2021; 292:416-423. DOI: 10.1016/j.jad.2021.05.119. View

Kwasny A, Wlodarczyk A, Dywel A, Szarmach J, Strandberg O, Cubala W . Residual insomnia in major depressive disorder: a systematic review. Front Psychiatry. 2023; 14:1190415. PMC: 10312086. DOI: 10.3389/fpsyt.2023.1190415. View

Robinson R, Stephenson J, Dennehy E, Grabner M, Faries D, Palli S . The importance of unresolved fatigue in depression: costs and comorbidities. Psychosomatics. 2015; 56(3):274-85. DOI: 10.1016/j.psym.2014.08.003. View

Addington A, Gallo J, Ford D, Eaton W . Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981-1994. Psychol Med. 2001; 31(6):1037-44. DOI: 10.1017/s0033291701004214. View

Wietecha L, Ruff D, Allen A, Greenhill L, Newcorn J . Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry. 2014; 74(12):1217-23. DOI: 10.4088/JCP.12m07991. View

Kroenke K, Wood D, Mangelsdorff A, Meier N, Powell J . Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA. 1988; 260(7):929-34. View

10.

Chung K, Yu Y, Yeung W . Correlates of residual fatigue in patients with major depressive disorder: The role of psychotropic medication. J Affect Disord. 2015; 186:192-7. DOI: 10.1016/j.jad.2015.07.026. View

11.

Grover S, Chakrabarti S, Sahoo S . Prevalence and clinical correlates of residual symptoms in remitted patients with bipolar disorder: An exploratory study. Indian J Psychiatry. 2020; 62(3):295-305. PMC: 7368443. DOI: 10.4103/psychiatry.IndianJPsychiatry_760_19. View

12.

Zhou J, Zhou J, Feng Z, Feng L, Xiao L, Chen X . Identifying the core residual symptom in patients with major depressive disorder using network analysis and illustrating its association with prognosis: A study based on the national cohorts in China. Gen Hosp Psychiatry. 2024; 87:68-76. DOI: 10.1016/j.genhosppsych.2024.01.012. View

13.

McClintock S, Husain M, Wisniewski S, Nierenberg A, Stewart J, Trivedi M . Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31(2):180-6. PMC: 3677201. DOI: 10.1097/JCP.0b013e31820ebd2c. View

14.

Gao K, Calabrese J . Prevalence and factors associated with fatigue in patients with major depressive disorder or bipolar disorder. J Affect Disord. 2024; 362:493-501. DOI: 10.1016/j.jad.2024.07.016. View

15.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

16.

Pastuszak M, Cubala W, Kwasny A, Mechlinska A . The Search for Consistency in Residual Symptoms in Major Depressive Disorder: A Narrative Review. J Pers Med. 2024; 14(8). PMC: 11355381. DOI: 10.3390/jpm14080828. View

17.

Wang Y, Wang G, Zhang N, Huang J, Wu W, Jia F . Association between residual symptoms and social functioning in patients with depression. Compr Psychiatry. 2020; 98:152164. DOI: 10.1016/j.comppsych.2020.152164. View

18.

DeBattista C, Doghramji K, Menza M, Rosenthal M, Fieve R . Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64(9):1057-64. DOI: 10.4088/jcp.v64n0911. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Thase M, Fava M, DeBattista C, Arora S, Hughes R . Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006; 11(2):93-102. DOI: 10.1017/s1092852900010622. View